Absci CEO envisions AI-driven, consumer-focused drug platform, eyeing hair loss, endometriosis and future GLP-1 combos

Absci, an AI‑focused biotech founded about 15 years ago in Vancouver, Washington, is led by CEO Sean McClain, who likens his ambition for the company to creating the Apple of biotech.

The surge in demand for GLP‑1 weight‑loss medicines has reshaped the market, giving consumers more direct influence over their health choices and lowering barriers to access.

Absci’s lead candidate, ABS‑201, is currently being developed for male pattern hair loss and endometriosis, both of which represent sizable therapeutic markets.

McClain envisions a model where the drug is periodically upgraded-much like a new iPhone generation-potentially combining ABS‑201 with a GLP‑1 agent to deliver both hair regrowth and weight‑loss benefits in a single, affordable treatment.